All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Neoleukin Therapeutics Inc. have described NEO-TRA1, a novel CD25-targeted de novo non-α agonist of the IL-2 receptor (IL-2R) designed to selectively expand Tregs.
